BR112014004352A2 - anticorpos anti-xcr1 humano - Google Patents
anticorpos anti-xcr1 humanoInfo
- Publication number
- BR112014004352A2 BR112014004352A2 BR112014004352A BR112014004352A BR112014004352A2 BR 112014004352 A2 BR112014004352 A2 BR 112014004352A2 BR 112014004352 A BR112014004352 A BR 112014004352A BR 112014004352 A BR112014004352 A BR 112014004352A BR 112014004352 A2 BR112014004352 A2 BR 112014004352A2
- Authority
- BR
- Brazil
- Prior art keywords
- human xcr1
- xcr1 antibodies
- antibodies
- amino acids
- binds
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/55—Fusion polypeptide containing a fusion with a toxin, e.g. diphteria toxin
Abstract
resumo anticorpos anti-xcr1 humano um objetivo da presente invenção consiste em proporcionar um anticorpo monoclonal que se liga ao xcr1 humano, em que o anticorpo se liga a epítopos lineares ou descontínuos que compreendem pelo menos três aminoácidos selecionados do grupo consistindo do 8º, 11º, 12º, 13º, 14º, 16º, 17º, 22º, 23º, 176º, e 177º aminoácidos da sequência de aminoácidos da seq id no: 91.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201161530194P | 2011-09-01 | 2011-09-01 | |
US201261659637P | 2012-06-14 | 2012-06-14 | |
PCT/JP2012/072667 WO2013032032A1 (en) | 2011-09-01 | 2012-08-30 | Anti-human xcr1 antibodies |
Publications (1)
Publication Number | Publication Date |
---|---|
BR112014004352A2 true BR112014004352A2 (pt) | 2017-03-21 |
Family
ID=46881120
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112014004352A BR112014004352A2 (pt) | 2011-09-01 | 2012-08-30 | anticorpos anti-xcr1 humano |
Country Status (18)
Country | Link |
---|---|
US (1) | US9371389B2 (pt) |
EP (1) | EP2751140B1 (pt) |
JP (1) | JP5989096B2 (pt) |
KR (1) | KR101767717B1 (pt) |
CN (1) | CN103764680B (pt) |
AR (1) | AR087749A1 (pt) |
AU (1) | AU2012302596B2 (pt) |
BR (1) | BR112014004352A2 (pt) |
CA (1) | CA2846370C (pt) |
ES (1) | ES2684173T3 (pt) |
HK (1) | HK1199038A1 (pt) |
IL (1) | IL231075A (pt) |
IN (1) | IN2014CN01466A (pt) |
MX (1) | MX346560B (pt) |
MY (1) | MY166152A (pt) |
RU (1) | RU2619180C2 (pt) |
TW (1) | TWI563004B (pt) |
WO (1) | WO2013032032A1 (pt) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BR112015032200A2 (pt) | 2013-06-24 | 2017-11-21 | Hanwha Chemical Corp | conjugado anticorpo-droga com estabilidade melhorada, método de preparação, composição farmacêutica e uso do mesmo |
BR112018002382A8 (pt) | 2015-08-05 | 2022-12-06 | Acticor Biotech | Novos anticorpos anti-gvpi humano e usos dos mesmos |
BR112019016065A8 (pt) | 2017-02-03 | 2022-10-18 | Acticor Biotech | Inibição da agregação de plaquetas usando anticorpos anti-humanos de gpvi |
US11246911B2 (en) | 2017-02-07 | 2022-02-15 | Vib Vzw | Immune-cell targeted bispecific chimeric proteins and uses thereof |
CN107312092B (zh) * | 2017-05-04 | 2020-12-11 | 华南农业大学 | 一种斜带石斑鱼ccr12的多克隆抗体制备方法及其应用 |
US20210130776A1 (en) * | 2017-09-29 | 2021-05-06 | The Broad Institute, Inc. | Methods and compositions for modulating suppression of lymphocyte activity |
WO2019148089A1 (en) * | 2018-01-26 | 2019-08-01 | Orionis Biosciences Inc. | Xcr1 binding agents and uses thereof |
CN113412123A (zh) | 2018-12-28 | 2021-09-17 | 豪夫迈·罗氏有限公司 | 用于免疫应答增强的患者的治疗性用途的肽-mhc-i-抗体融合蛋白 |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
US5786210A (en) | 1994-02-08 | 1998-07-28 | Schering Corporation | Mammalian thymokine genes |
EP1268554A2 (de) * | 2000-03-31 | 2003-01-02 | IPF Pharmaceuticals GmbH | Diagnostik- und arzneimittel zur untersuchung des zelloberflächenproteoms von tumor- und entzündungszellen sowie zur behandlung von tumorerkrankungen und entzündlichen erkrankungen vorzugsweise mit hilfe einer spezifischen chemokinrezeptor-analyse und der chemokinrezeptor-ligand-interaktion |
AU2002246557A1 (en) * | 2000-11-29 | 2002-08-06 | Lifespan Biosciences, Inc. | Compositions and methods related to chemokine (c motif) xc receptor 1 (ccxcr1) |
US20050136033A9 (en) * | 2002-08-13 | 2005-06-23 | Matthias Mack | Method of treating allergen induced airway disease |
WO2004072646A1 (en) * | 2003-02-13 | 2004-08-26 | Bayer Healthcare Ag | Diagnostics and therapeutics for diseases associated with g protein-coupled receptor 5 (gpr5) |
EP1698902A1 (en) * | 2005-03-01 | 2006-09-06 | DKFZ Deutsches Krebsforschungszentrum | Use of XCR1 for diagnosing or monitoring of immune tolerance |
CN101293924A (zh) * | 2007-04-24 | 2008-10-29 | 上海国健生物技术研究院 | 骨桥蛋白的功能表位、与其特异性结合的单克隆抗体及其在制备抗肿瘤转移药物中的用途 |
EP2062592A1 (en) * | 2007-11-20 | 2009-05-27 | BUNDESREPUBLIK DEUTSCHLAND letztvertreten durch das Robert Koch-Institut vertreten durch seinen Präsidenten | System for delivery into a XCR1 positive cell and uses thereof |
CN102439163A (zh) | 2009-02-16 | 2012-05-02 | 拜奥雷克斯治疗公司 | 人源化抗cd20抗体及使用方法 |
-
2012
- 2012-08-30 MY MYPI2014700412A patent/MY166152A/en unknown
- 2012-08-30 AU AU2012302596A patent/AU2012302596B2/en not_active Ceased
- 2012-08-30 JP JP2014509528A patent/JP5989096B2/ja not_active Expired - Fee Related
- 2012-08-30 RU RU2014106832A patent/RU2619180C2/ru not_active IP Right Cessation
- 2012-08-30 EP EP12761822.1A patent/EP2751140B1/en not_active Not-in-force
- 2012-08-30 ES ES12761822T patent/ES2684173T3/es active Active
- 2012-08-30 WO PCT/JP2012/072667 patent/WO2013032032A1/en active Application Filing
- 2012-08-30 US US14/240,090 patent/US9371389B2/en not_active Expired - Fee Related
- 2012-08-30 CN CN201280041366.2A patent/CN103764680B/zh not_active Expired - Fee Related
- 2012-08-30 IN IN1466CHN2014 patent/IN2014CN01466A/en unknown
- 2012-08-30 TW TW101131633A patent/TWI563004B/zh not_active IP Right Cessation
- 2012-08-30 CA CA2846370A patent/CA2846370C/en not_active Expired - Fee Related
- 2012-08-30 AR ARP120103217A patent/AR087749A1/es unknown
- 2012-08-30 KR KR1020147004507A patent/KR101767717B1/ko active IP Right Grant
- 2012-08-30 BR BR112014004352A patent/BR112014004352A2/pt not_active Application Discontinuation
- 2012-08-30 MX MX2014002078A patent/MX346560B/es active IP Right Grant
-
2014
- 2014-02-20 IL IL231075A patent/IL231075A/en active IP Right Grant
- 2014-12-09 HK HK14112359.4A patent/HK1199038A1/xx unknown
Also Published As
Publication number | Publication date |
---|---|
IL231075A (en) | 2017-08-31 |
EP2751140A1 (en) | 2014-07-09 |
TW201311725A (zh) | 2013-03-16 |
KR20140054108A (ko) | 2014-05-08 |
JP2014527396A (ja) | 2014-10-16 |
US20140193421A1 (en) | 2014-07-10 |
US9371389B2 (en) | 2016-06-21 |
MY166152A (en) | 2018-06-06 |
WO2013032032A1 (en) | 2013-03-07 |
MX2014002078A (es) | 2014-05-30 |
CA2846370A1 (en) | 2013-03-07 |
AU2012302596A1 (en) | 2014-03-06 |
CA2846370C (en) | 2019-04-23 |
RU2619180C2 (ru) | 2017-05-12 |
ES2684173T3 (es) | 2018-10-01 |
EP2751140B1 (en) | 2018-05-30 |
NZ621320A (en) | 2015-11-27 |
AR087749A1 (es) | 2014-04-16 |
MX346560B (es) | 2017-03-24 |
KR101767717B1 (ko) | 2017-08-11 |
HK1199038A1 (en) | 2015-06-19 |
IN2014CN01466A (pt) | 2015-05-08 |
IL231075A0 (en) | 2014-03-31 |
CN103764680B (zh) | 2016-11-23 |
AU2012302596B2 (en) | 2016-12-01 |
JP5989096B2 (ja) | 2016-09-07 |
TWI563004B (en) | 2016-12-21 |
RU2014106832A (ru) | 2015-08-27 |
CN103764680A (zh) | 2014-04-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR112014004352A2 (pt) | anticorpos anti-xcr1 humano | |
BR112014005644A2 (pt) | anticorpo anti-alfabetatcr | |
CY1120398T1 (el) | Ανθρωποποιημενα αντισωματα που αναγνωριζουν αλφα-συνουκλεϊνη | |
UA115439C2 (uk) | Гуманізоване антитіло, яке розпізнає альфа-синуклеїн | |
NZ607969A (en) | Cd33 binding agents | |
UA116873C2 (uk) | Антитіло, яке зв'язується з ox40 | |
BR112016013347A2 (pt) | anticorpo monoclonal humano neutralizante anti-il-33 | |
UA113623C2 (uk) | Моноклональне антитіло проти інгібітору шляху тканинного фактора (tfpi) | |
UA117097C2 (uk) | Антитіло проти лігандів рецептора в1 брадикініну | |
BR112013033258A8 (pt) | Anticorpo isolado ou fragmento de ligação ao antígeno do mesmo que se liga a alfa-sinucleína, composição e seus usos | |
PE20141162A1 (es) | Anticuerpos anti-il-23 | |
MY153893A (en) | Antibodies against human il17 and uses thereof | |
UA114891C2 (uk) | ІЗОЛЬОВАНЕ АНТИТІЛО ЛЮДИНИ, ЯКЕ СПЕЦИФІЧНО ЗВ'ЯЗУЄТЬСЯ З АНГІОПОЕТИНПОДІБНИМ БІЛКОМ 3 ЛЮДИНИ (hАNGPTL3), ТА ЙОГО ЗАСТОСУВАННЯ | |
NZ597023A (en) | Monoclonal antibodies that bind to hGM-CSF and medical compositions comprising same | |
SG195073A1 (en) | Deimmunized serum-binding domains and their use for extending serum half-life | |
UA111818C2 (uk) | Антитіло проти csf-1r | |
CR20120359A (es) | Anticuerpos anti-il-10 humanizados para el tratamiento de lupus sistemico eritematoso (sle) | |
BR112013027631A2 (pt) | Método para a produção de anticorpo monoclonal ou fragmento que inclui uma região de ligação ao antígeno do mesmo, anticorpo monoclonal ou um fragmento que inclui uma região de 5 ligação ao antígeno do mesmo, hibridoma, método para a detecção de uma célula dendrítica plasmocitóide, uso de um anticorpo monoclonal ou um fragmento que inclui uma região de ligação ao antígeno do mesmo, e método ex vivo para suprimir a atividade de uma célula dendrítica plasmocitóide | |
EA201070539A1 (ru) | НОВЫЕ АНТИТЕЛА, СПЕЦИФИЧНЫЕ К β-АМИЛОИДНЫМ ПЕПТИДАМ, И ИХ ПРИМЕНЕНИЕ В КАЧЕСТВЕ ДИАГНОСТИЧЕСКИХ ИЛИ ЛЕКАРСТВЕННЫХ СРЕДСТВ | |
NZ629553A (en) | Anti-big-endothelin-1 (big-et-1) antibodies and uses thereof | |
BR112014027991A2 (pt) | agentes para neutralização de influenza | |
BR112021021281A2 (pt) | Anticorpo monoclonal que se liga especificamente ao gitr | |
EA201270701A1 (ru) | Ингибирующие металлопротеины антитела | |
MA38161A1 (fr) | Anticorps anti-bmp-6 | |
BR112014025560A2 (pt) | anticorpos anti-pdgf-c |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] |
Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI |
|
B11B | Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements |